Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel H Fowler

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Molecular Therapy. Methods & Clinical Development|February 23, 2023
Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry diseaseAmr H Saleh, Michael Rothe, Dwayne L Barber, et al.
Science Translational Medicine|December 3, 2011
The PDL1-PD1 axis converts human TH1 cells into regulatory T cellsShoba Amarnath, Courtney W Mangus, James C M Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2017
Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease PatientsLauren M Curtis, Filip Pirsl, Seth M Steinberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 3, 2005
Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patientsClaude Sportès, Nicole J McCarthy, Frances Hakim, et al.
Blood|June 5, 2008
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse populationSumithira Vasu, Susan F Leitman, John F Tisdale, et al.
British Journal of Haematology|September 9, 2004
Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantationMichael R Bishop, Seth M Steinberg, Ronald E Gress, et al.
Immunity|May 21, 2015
Interleukin-2 activity can be fine tuned with engineered receptor signaling clampsSuman Mitra, Aaron M Ring, Shoba Amarnath, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 8, 2016
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseKenneth R Cooke, Leo Luznik, Stefanie Sarantopoulos, et al.
Blood|February 7, 2004
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cellsKouhei Yamashita, Uimook Choi, Patricia C Woltz, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 11, 2020
<sup>90</sup>Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's LymphomaKevin C Conlon, Claude Sportes, Martin W Brechbiel, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Molecular Therapy. Methods & Clinical Development|February 23, 2023
Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry diseaseAmr H Saleh, Michael Rothe, Dwayne L Barber, et al.
Science Translational Medicine|December 3, 2011
The PDL1-PD1 axis converts human TH1 cells into regulatory T cellsShoba Amarnath, Courtney W Mangus, James C M Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2017
Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease PatientsLauren M Curtis, Filip Pirsl, Seth M Steinberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 3, 2005
Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patientsClaude Sportès, Nicole J McCarthy, Frances Hakim, et al.
Blood|June 5, 2008
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse populationSumithira Vasu, Susan F Leitman, John F Tisdale, et al.
British Journal of Haematology|September 9, 2004
Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantationMichael R Bishop, Seth M Steinberg, Ronald E Gress, et al.
Immunity|May 21, 2015
Interleukin-2 activity can be fine tuned with engineered receptor signaling clampsSuman Mitra, Aaron M Ring, Shoba Amarnath, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 8, 2016
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseKenneth R Cooke, Leo Luznik, Stefanie Sarantopoulos, et al.
Blood|February 7, 2004
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cellsKouhei Yamashita, Uimook Choi, Patricia C Woltz, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 11, 2020
<sup>90</sup>Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's LymphomaKevin C Conlon, Claude Sportes, Martin W Brechbiel, et al.
Pageof 10